Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
ZT ZTS Zoetis Inc. FY ended Feb 06, 2026 | $77.34 | $31.96B | $41.06B | $9.47B | $4.07B | $2.67B | 12.85x | 3.38x | 9.38x |
EL ELAN Elanco Animal Health Inc FY ended Feb 19, 2026 | $24.11 | $12.05B | $15.41B | $4.72B | $691.00M | -$232.00M | -51.30x | 2.55x | 17.18x |
MR MRK Merck & Co., Inc. FY ended Jan 31, 2026 | $148.35 | $366.00B | $392.48B | $65.01B | $28.05B | $18.25B | 20.38x | 5.63x | 13.37x |
VT VTRS Viatris Inc FY ended Feb 23, 2026 | — | — | — | $14.30B | -$469.30M | -$3.51B | — | — | — |
HR HROW HARROW, INC. FY ended Feb 25, 2026 | — | — | — | $272.30M | $38.35M | -$5.14M | — | — | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 12.89x | 3/5 | $1.85B | $26.90 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 3.85x | 3/5 | $5.85B | $84.89 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -6.02x | 3/5 | -$600.74M | — | Peer averages are not economically meaningful for this method. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
ZT ZTS Zoetis Inc. FY ended Feb 06, 2026 | $77.34 | $31.96B | $41.06B | $9.47B | $4.07B | $2.67B | 12.85x | 3.38x | 9.38x |
EL ELAN Elanco Animal Health Inc FY ended Feb 19, 2026 | $24.11 | $12.05B | $15.41B | $4.72B | $691.00M | -$232.00M | -51.30x | 2.55x | 17.18x |
MR MRK Merck & Co., Inc. FY ended Jan 31, 2026 | $148.35 | $366.00B | $392.48B | $65.01B | $28.05B | $18.25B | 20.38x | 5.63x | 13.37x |
VT VTRS Viatris Inc FY ended Feb 23, 2026 | — | — | — | $14.30B | -$469.30M | -$3.51B | — | — | — |
HR HROW HARROW, INC. FY ended Feb 25, 2026 | — | — | — | $272.30M | $38.35M | -$5.14M | — | — | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 12.89x | 3/5 | $1.85B | $26.90 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 3.85x | 3/5 | $5.85B | $84.89 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | -6.02x | 3/5 | -$600.74M | — | Peer averages are not economically meaningful for this method. |
